ImmunoBrain Reports Phase 1b Results for Novel PD-L1 Checkpoint Inhibitor in Alzheimer's Disease
核心洞察
ImmunoBrain (搜索) will present Phase 1b clinical data for IBC-Ab002, a proprietary anti-PD-L1 (搜索) monoclonal antibody designed for Alzheimer's disease (搜索) treatment, at the AD/PD 2026 conference in Copenhagen.
The presentation will include safety, tolerability and biomarker data from the first 40 patients who received four intravenous infusions across five escalating dose cohorts in the IBC-01-01 study.
IBC-Ab002 represents a novel approach using immune checkpoint blockade to activate the peripheral immune system for brain protection and repair in neurodegenerative diseases (搜索).
ImmunoBrain (搜索), a clinical-stage biopharmaceutical company, announced that topline Phase 1b clinical data for its investigational Alzheimer's disease (搜索) therapy IBC-Ab002 will be presented at the 2026 Alzheimer's and Parkinson's Diseases Conference (AD/PD™) in Copenhagen, Denmark, March 17-21, 2026. The presentation will feature safety, tolerability and biomarker data from the first 40 patients treated in the IBC-01-01 study.
Novel Immune Checkpoint Approach
IBC-Ab002 is a newly engineered proprietary antibody targeting an inhibitory immune checkpoint pathway, specifically tailored for Alzheimer's disease (搜索) and other neurodegenerative disorders. The therapy represents a differentiated approach that activates the peripheral immune system to support brain protection and repair, marking a departure from traditional Alzheimer's treatment strategies.
The investigational drug is designed as a proprietary Fc-modified anti-PD-L1 (搜索) monoclonal antibody engineered for transient checkpoint blockade and intermittent dosing in chronic neurodegenerative diseases (搜索). This approach builds on the understanding that the brain is tightly dependent on the viability of the immune system and that immune function plays a critical role in protecting and repairing brain tissue.
Phase 1b Study Design and Results
The Phase 1b clinical trial (NCT05551741) evaluated IBC-Ab002 across five escalating dose cohorts, with patients receiving four intravenous infusions of either the active treatment or placebo. The study's primary focus was assessing safety and tolerability while collecting biomarker data to understand the therapy's biological effects.
Professor Catherine J. Mummery, M.B.B.S., Ph.D., F.R.C.P., will present the topline results during the "Mechanistic Modifiers of AD: APOE, Immunity, and Neural Circuits" session on Thursday, March 19, 2026, at 8:55 a.m. CET in Hall 180-181. The presentation, titled "PD-L1 (搜索) Immune Checkpoint Blockade in Early Alzheimer's Disease (搜索): Topline Results from the Phase 1b IBC-01-01 Study," will provide the first comprehensive look at the therapy's clinical performance.
Scientific Foundation
The therapeutic approach is grounded in more than 25 years of research led by Scientific Co-Founder and Chief Scientific Officer Professor Michal Schwartz, Ph.D., and her team at the Weizmann Institute of Science. Their research discovered that the brain is tightly dependent on immune system viability and that immune function plays a critical role in brain protection and repair mechanisms.
This scientific foundation challenges traditional views of neuroinflammation in Alzheimer's disease (搜索) and suggests that strategic immune system activation, rather than suppression, may offer therapeutic benefits for neurodegenerative conditions.
Regulatory and Funding Support
The Phase 1b clinical trial received support from grants provided by the National Institute on Aging (NIA) and the Alzheimer's Association. Specifically, the research is supported by the National Institutes of Health's National Institute on Aging under Award Number R01AG071810, highlighting the scientific merit and potential impact of this novel therapeutic approach.
The company has recently completed its Phase 1b clinical trial in patients with Alzheimer's disease (搜索), positioning IBC-Ab002 for potential advancement into later-stage clinical development pending the results being presented at the upcoming conference.